European Cancer Congress 2015

• 6 abstracts accepted including latest data for GIOTRIF^® (afatinib*) and VARGATEF^® (nintedanib**) in lung cancer and beyond
• Latest data from LUME-Lung 1 trial demonstrate VARGATEF^® plus docetaxel reduced the rate of tumour growth over time compared to docetaxel alone in second-line adenocarcinoma
• New analyses from LUX-Lung 8 trial provides further information to support the use of GIOTRIF^® to treat patients with squamous cell carcinoma (SCC) of the lung, independent of their mutation status^2,3

Disclaimer: Not an official event at the European Cancer Congress (ECC) 2015. Not sponsored or endorsed by ECC

*Afatinib is approved in a number of markets, including the EU, Japan, Taiwan and Canada under the brand name GIOTRIF^® and in the U.S. under the brand name GILOTRIF^® for use in patients with specific types of EGFR mutation-positive non-small cell lung cancer (NSCLC). Registration conditions differ internationally, please refer to locally approved prescribing information. Afatinib is under regulatory review by health authorities in other countries worldwide. Afatinib is not approved in other indications.
**Nintedanib is approved in the EU under the brand name VARGATEF^® for use in combination with docetaxel in adult patients with locally advanced, metastatic or locally recurrent NSCLC of adenocarcinoma tumour histology after first-linechemotherapy. Nintedanib is under regulatory review by health authorities in other countries outside the EU. Nintedanib is not approved in other oncology indications.

¹Reck et al. Tumour Growth over Time in Patients with Advanced Non-small Cell Lung Cancer Treated with Nintedanib plus Docetaxel or Placebo plus Docetaxel: Analysis of Data from the LUME-Lung 1 Study. To be presented at European Cancer Congress, 25-29 September 2015, Vienna, Austria.

²Goss et al. Phase III trial of afatinib vs erlotinib in patients with squamous cell carcinoma (SCC) of the lung (LUX-Lung 8): EGFR molecular aberrations and survival outcomes. To be presented at European Cancer Congress, 25-29 September 2015, Vienna, Austria.

³Popat et al. Second-line afatinib vs erlotinib in patients with advanced squamous cell carcinoma (SCC) of the lung: patient-reported outcome (PRO) data from the global LUX-Lung 8 (LL8) Phase III trial. To be presented at European Cancer Congress, 25-29 September 2015, Vienna, Austria.